Literature DB >> 9060663

Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector.

I J Caley1, M R Betts, D M Irlbeck, N L Davis, R Swanstrom, J A Frelinger, R E Johnston.   

Abstract

A molecularly cloned attenuated strain of Venezuelan equine encephalitis virus (VEE) has been genetically configured as a replication-competent vaccine vector for the expression of heterologous viral proteins (N. L. Davis, K. W. Brown, and R. E. Johnston, J. Virol. 70:3781-3787, 1996). The matrix/capsid (MA/CA) coding domain of human immunodeficiency virus type 1 (HIV-1) was cloned into the VEE vector to determine the ability of a VEE vector to stimulate an anti-HIV immune response in mice. The VEE-MA/CA vector replicated rapidly in the cytoplasm of baby hamster kidney (BHK) cells and expressed large quantities of antigenically identifiable MA/CA protein. When injected subcutaneously into BALB/c mice, the vector invaded and replicated in the draining lymphoid tissues, expressing HIV-1 MA/CA at a site of potent immune activity. Anti-MA/CA immunoglobulin G (IgG) and IgA antibodies were present in serum of all immunized mice, and titers increased after a second booster inoculation. IgA antibodies specific for MA/CA were detected in vaginal washes of mice that received two subcutaneous immunizations. Cytotoxic T-lymphocyte responses specific for MA/CA were detected following immunization with the MA/CA-expressing VEE vector. These findings demonstrate the ability of a VEE-based vaccine vector system to stimulate a comprehensive humoral and cellular immune response. The multifaceted nature of this response makes VEE an attractive vaccine for immunization against virus infections such as HIV-1, for which the correlates of protective immunity remain unclear, but may include multiple components of the immune system.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9060663      PMCID: PMC191432     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

1.  Persistence in humans of antibody to subtypes of Venezuelan equine encephalomyelitis (VEE) virus after immunization with attenuated (TC-83) VEE virus vaccine.

Authors:  D S Burke; H H Ramsburg; R Edelman
Journal:  J Infect Dis       Date:  1977-09       Impact factor: 5.226

2.  Complete nucleotide sequences of functional clones of the AIDS virus.

Authors:  L Ratner; A Fisher; L L Jagodzinski; H Mitsuya; R S Liou; R C Gallo; F Wong-Staal
Journal:  AIDS Res Hum Retroviruses       Date:  1987       Impact factor: 2.205

3.  Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.

Authors:  P W Berman; T J Gregory; L Riddle; G R Nakamura; M A Champe; J P Porter; F M Wurm; R D Hershberg; E K Cobb; J W Eichberg
Journal:  Nature       Date:  1990-06-14       Impact factor: 49.962

4.  RNA viruses as gene expression vectors.

Authors:  H V Huang; C M Rice; C Xiong; S Schlesinger
Journal:  Virus Genes       Date:  1989-09       Impact factor: 2.332

5.  Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector.

Authors:  V Karacostas; K Nagashima; M A Gonda; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

6.  Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques.

Authors:  T Lehner; Y Wang; M Cranage; L A Bergmeier; E Mitchell; L Tao; G Hall; M Dennis; N Cook; R Brookes; L Klavinskis; I Jones; C Doyle; R Ward
Journal:  Nat Med       Date:  1996-07       Impact factor: 53.440

7.  Protective efficacies of live attenuated and formaldehyde-inactivated Venezuelan equine encephalitis virus vaccines against aerosol challenge in hamsters.

Authors:  P B Jahrling; E H Stephenson
Journal:  J Clin Microbiol       Date:  1984-03       Impact factor: 5.948

8.  Recombinant vaccinia virus/Venezuelan equine encephalitis (VEE) virus protects mice from peripheral VEE virus challenge.

Authors:  R M Kinney; J J Esposito; J H Mathews; B J Johnson; J T Roehrig; A D Barrett; D W Trent
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

9.  Sindbis virus: an efficient, broad host range vector for gene expression in animal cells.

Authors:  C Xiong; R Levis; P Shen; S Schlesinger; C M Rice; H V Huang
Journal:  Science       Date:  1989-03-03       Impact factor: 47.728

10.  Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus.

Authors:  M Girard; M P Kieny; A Pinter; F Barre-Sinoussi; P Nara; H Kolbe; K Kusumi; A Chaput; T Reinhart; E Muchmore
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-15       Impact factor: 11.205

View more
  42 in total

1.  Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles.

Authors:  N L Davis; I J Caley; K W Brown; M R Betts; D M Irlbeck; K M McGrath; M J Connell; D C Montefiori; J A Frelinger; R Swanstrom; P R Johnson; R E Johnston
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

2.  Anti-tumor effect of the alphavirus-based virus-like particle vector expressing prostate-specific antigen in a HLA-DR transgenic mouse model of prostate cancer.

Authors:  V Riabov; I Tretyakova; R B Alexander; P Pushko; E N Klyushnenkova
Journal:  Vaccine       Date:  2015-08-28       Impact factor: 3.641

3.  Structure and immunogenicity of alternative forms of the simian immunodeficiency virus gag protein expressed using Venezuelan equine encephalitis virus replicon particles.

Authors:  Chad Cecil; Ande West; Martha Collier; Christy Jurgens; Victoria Madden; Alan Whitmore; Robert Johnston; Dominic T Moore; Ronald Swanstrom; Nancy L Davis
Journal:  Virology       Date:  2007-02-01       Impact factor: 3.616

4.  A novel self-replicating chimeric lentivirus-like particle.

Authors:  Christy K Jurgens; Kelly R Young; Victoria J Madden; Philip R Johnson; Robert E Johnston
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

5.  Systemic, mucosal, and heterotypic immune induction in mice inoculated with Venezuelan equine encephalitis replicons expressing Norwalk virus-like particles.

Authors:  Patrick R Harrington; Boyd Yount; Robert E Johnston; Nancy Davis; Christine Moe; Ralph S Baric
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

6.  Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag.

Authors:  Danilo R Casimiro; Fubao Wang; William A Schleif; Xiaoping Liang; Zhi-Qiang Zhang; Timothy W Tobery; Mary-Ellen Davies; Adrian B McDermott; David H O'Connor; Arthur Fridman; Ansu Bagchi; Lynda G Tussey; Andrew J Bett; Adam C Finnefrock; Tong-ming Fu; Aimin Tang; Keith A Wilson; Minchun Chen; Helen C Perry; Gwendolyn J Heidecker; Daniel C Freed; Anthony Carella; Kara S Punt; Kara J Sykes; Lingyi Huang; Virginia I Ausensi; Margaret Bachinsky; Usha Sadasivan-Nair; David I Watkins; Emilio A Emini; John W Shiver
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

Review 7.  RNA virus vectors: where are we and where do we need to go?

Authors:  P Palese
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

8.  Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV.

Authors:  I Ourmanov; C R Brown; B Moss; M Carroll; L Wyatt; L Pletneva; S Goldstein; D Venzon; V M Hirsch
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

9.  Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge.

Authors:  A Seth; I Ourmanov; J E Schmitz; M J Kuroda; M A Lifton; C E Nickerson; L Wyatt; M Carroll; B Moss; D Venzon; N L Letvin; V M Hirsch
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

10.  A heterologous DNA prime-Venezuelan equine encephalitis virus replicon particle boost dengue vaccine regimen affords complete protection from virus challenge in cynomolgus macaques.

Authors:  Lan Chen; Dan Ewing; Hemavathy Subramanian; Karla Block; Jonathan Rayner; Kimberly D Alterson; Martha Sedegah; Curtis Hayes; Kevin Porter; Kanakatte Raviprakash
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.